”Big pharmas don’t have the luxury …” - love this opinion of yours.
Barring an easy takeover, what will be a second best option for these behemoths then? Pay up with cold, hard cash and/or access to their infrastructure perhaps? Sounds good and makes a lot of sense to me, especially when quite a few will be going down patent cliffs in the next 3-5 years. The dollars will have to be big though, given how much near and mid-term potential this company’s portfolio of assets holds. It boggles the mind.
Only a matter of time - in short order, dare we say?
DYOR, make up your own mind.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.38 |
Change
-0.070(2.86%) |
Mkt cap ! $3.046B | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.48 | $2.35 | $8.936M | 3.711M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 34219 | $2.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.39 | 25304 | 4 |
View Market Depth
| Last trade - 16.15pm 31/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |